Next-Generation Curcumin-Based NK3 Receptor Antagonists
Legal Citation
Summary of the Inventive Concept
A next-generation system for NK3 receptor antagonism utilizing novel curcumin compositions, formulations, and delivery methods to achieve improved bioavailability, targeted delivery, and personalized treatment regimens.
Background and Problem Solved
The original patent disclosed curcumin compositions and methods for NK3 receptor antagonism, but limitations in bioavailability, delivery, and personalized treatment approaches hindered its full potential. The new inventive concept addresses these limitations by introducing novel molecular structures, synergistic ratios, and delivery methods.
Detailed Description of the Inventive Concept
The next-generation system comprises a curcumin composition with a novel molecular structure, administered through a transdermal patch for improved bioavailability and sustained release. Alternatively, the composition can be formulated as a nanoparticle for targeted delivery to the central nervous system or as an oral pharmaceutical composition with improved pharmacokinetics. A wearable device with a micro-needling system enables transcranial delivery, and a computer-implemented system predicts individual responses to curcumin compositions and recommends tailored treatment regimens.
Novelty and Inventive Step
The new inventive concept introduces novel molecular structures, synergistic ratios, and delivery methods that are not obvious from the original patent. The combination of these elements provides a next-generation system for NK3 receptor antagonism with improved efficacy and personalized treatment approaches.
Alternative Embodiments and Variations
Other embodiments of the inventive concept could include aerosolized delivery, implantable devices, or topical creams. Variations of the synergistic ratios, nanoparticle formulations, and wearable devices could also be explored to further expand the conceptual coverage.
Potential Commercial Applications and Market
The next-generation system has significant commercial potential in the pharmaceutical industry, particularly in the treatment of neurokinin-3 mediated disorders. The personalized treatment approach and improved bioavailability could also expand the market to include novel applications in pain management, inflammation, and neurological disorders.
CPC Classifications
| Section | Class | Group |
|---|---|---|
| A | A61 | A61K36/9066 |
| A | A61 | A61K31/26 |
| A | A61 | A61K36/82 |
| A | A61 | A61P15/12 |
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Pharmaceutical compositions, neuropharmacology, and natural product-based drug delivery systems, with expertise in receptor antagonist formulations and personalized medicine approaches
Person of Ordinary Skill (PHOSITA) Profile
A professional with advanced degrees in pharmaceutical sciences or biochemistry, experienced in drug formulation, receptor pharmacology, and emerging drug delivery technologies, familiar with natural product-based therapeutic strategies
Obviousness Rationale
A skilled practitioner would recognize that the PTD represents predictable extensions of the source patent's curcumin-based NK3 receptor antagonist approach, utilizing known pharmaceutical engineering techniques to improve bioavailability, delivery, and personalization of the original composition. The variations represent standard optimization strategies within the established framework of the source patent's core invention. The technical modifications demonstrate incremental improvements using conventional pharmaceutical development methodologies.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,594 |
|---|---|
| Title | Curcumin compositions and methods of use as an NK3 antagonist |
| Assignee(s) | JDS Therapeutics, LLC |